BOSTON – Biognosys, a Swiss next-gen proteomics company announced that it will open its new North American office in Greater Boston, Massachusetts in Q2 this year. The office will be the firm’s first North American location. The Massachusetts Life Sciences Center has worked closely with Biognosys on their location selection decision.
Earlier this year, Biognosys shared that it had received significant funding from a corporate investment fund and its plans to use the Series C financing round to establish business development and service operations in the US., and to develop new workflows and products for high-content protein analysis.
“We welcome Biognosys to Massachusetts and look forward to having them be a part of our thriving life sciences community,” said Governor Charlie Baker. “Massachusetts is a great place for international life sciences companies that are looking to enter the U.S. market to locate and do business.”
“The Boston area is perhaps the most dynamic biopharma cluster in the United States today. The proximity to so many great life science companies, the support from organizations such as the MLSC and the small time zone difference to Europe make Boston an ideal location for a European biotech company looking to establish US operations,” said Stephan van Sint Fiet, Chief Commercial Officer of Biognosys.
“I would like to extend our congratulations to Biognosys on their decision to establish their first U.S. office in the Greater Boston area,” said Travis McCready, President & CEO of the Massachusetts Life Sciences Center. “The MLSC has been working closely with Biognosys as they considered their U.S. location options. Mass spectrometry based proteomics has become an indispensable tool in the cellular and molecular life sciences. This new office will enable Biognosys to make important contributions to the Massachusetts life sciences community, in the world’s leading ecosystem for life sciences innovation and growth.”
“We are thrilled to welcome MassBio member Biognosys to the Massachusetts life sciences supercluster,” said Robert K. Coughlin, President & CEO of MassBio. “We know they will bring value to and benefit from our robust biotechnology community as they grow and connect with new partners.”
Biognosys is a leading company in next-generation proteomics. Biognosys makes next-gen proteomics widely available through its services, the software products for analysis of mass spectrometric data and accompanying workflow and quantification kits. Their technology quantifies proteins with unbeatable precision and depth.
